Allarity Therapeutics, Inc.
ALLRHealthcare|Biotechnology|US
$0.96
-0.01 (-1.13%)
DCF Value
$1.18
Tangible Book / Share
$0.22
Cash / Share
$1.07
Financials
Financial Snapshot
Market Cap
$15.4M
Enterprise Value
$20.7M
Revenue (TTM)
$345.0K
Net Income (TTM)
-$12.3M
Cash & Investments
$17.0M
Net Cash
-$5.3M
Free Cash Flow (TTM)
-$13.8M
Operating CF (TTM)
-$13.7M
Debt/Equity
6.30
Cash Runway & Burn Rate
Cash on Hand
$17.0M
Quarterly Burn
$3.4M
Monthly Burn
$1.1M
Est. Runway
~5.0 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $2.1M | $536.0K | $237.4K | $1.5M | $298.0K | $19.9M | $2.0M | $166.0K | $19.5M | $14.7M | $17.0M | |
| Operating Cash Flow | -$4.0M | -$1.3M | -$4.2M | -$10.1M | -$7.3M | -$15.1M | -$16.8M | -$12.7M | -$17.4M | -$14.8M | -$13.7M | |
| Free Cash Flow | -$4.1M | -$1.3M | -$4.2M | -$10.1M | -$7.3M | -$15.1M | -$16.8M | -$12.7M | -$17.6M | -$14.8M | -$13.8M | |
| Capital Expenditure | -$77.8K | $0.00 | -$5.7K | -$8.0K | -$3.0K | $0.00 | -$18.0K | $0.00 | -$298.0K | -$8.0K | -$64.0K | |
| Financing Cash Flow | $4.3M | $1.2M | $2.4M | $11.2M | $6.0M | $33.8M | -$1.3M | $11.0M | $36.8M | $10.6M | $21.8M |
R&D Spending
R&D (TTM)
$5.5M
R&D Intensity
1599.7%
R&D Growth vs Prior
-16.4%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $143.3K | $1.5M | $1.5M | $120.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $320.0K | $345.0K | |
| R&D Expense | $0.00 | $0.00 | $0.00 | $6.4M | $4.2M | $14.2M | $6.9M | $7.1M | $6.1M | $6.6M | $5.5M | |
| R&D % of Revenue | 0.0% | 0.0% | 0.0% | 5305.8% | — | — | — | — | — | 2062.8% | 1599.7% | |
| SG&A | $272.4K | $3.1M | $1.3M | $3.9M | $4.1M | $12.4M | $10.0M | $10.0M | $11.4M | $6.3M | $5.6M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $143.3K | $1.5M | $1.5M | $120.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $320.0K | $345.0K | |
| Cost of Revenue | $0.00 | $2.2M | $5.1M | $0.00 | $0.00 | $106.0K | $120.0K | $0.00 | $0.00 | $0.00 | -$26.0K | |
| Gross Profit | $143.3K | -$761.5K | -$3.6M | $120.0K | $0.00 | -$106.0K | -$120.0K | $0.00 | $0.00 | $320.0K | $371.0K | |
| R&D | $0.00 | $0.00 | $0.00 | $6.4M | $4.2M | $14.2M | $6.9M | $7.1M | $6.1M | $6.6M | $5.5M | |
| SG&A | $272.4K | $3.1M | $1.3M | $3.9M | $4.1M | $12.4M | $10.0M | $10.0M | $11.4M | $6.3M | $5.6M | |
| Operating Income | -$4.5M | -$3.8M | -$5.0M | -$17.6M | -$8.3M | -$26.6M | -$34.5M | -$17.1M | -$27.2M | -$12.6M | -$10.8M | |
| Interest Expense | $43.7K | $2.4K | $233.2K | $3.3M | $320.0K | $640.0K | $223.0K | $498.0K | $653.0K | $185.0K | $1.1M | |
| Pretax Income | -$4.4M | -$5.0M | -$3.5M | -$19.0M | -$6.4M | -$26.5M | -$17.6M | -$11.8M | -$24.9M | -$11.2M | -$12.3M | |
| Net Income | -$3.7M | -$4.9M | -$2.3M | -$14.3M | -$6.6M | -$26.6M | -$16.1M | -$11.9M | -$24.5M | -$11.2M | -$12.3M | |
| EPS (Diluted) | 0.00 | 0.00 | 0.00 | -189613.00 | -1698639.00 | -79074.18 | -31799.09 | -6031.31 | -15.79 | -0.78 | -0.78 | |
| EBITDA | -$4.2M | -$3.8M | -$4.9M | -$15.6M | -$6.1M | -$25.8M | -$17.3M | -$11.3M | -$24.2M | -$11.0M | -$11.1M | |
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.01 | 0.01 | 3.32 | 1.61 | 14.38 | 15.91 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.1M | $536.0K | $237.4K | $1.5M | $298.0K | $19.6M | $2.0M | $166.0K | $19.5M | $14.7M | $17.0M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $350.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $4.4M | $1.3M | $2.2M | $3.3M | $1.7M | $21.4M | $5.0M | $2.0M | $22.3M | $17.9M | $31.7M | |
| Total Assets | $6.5M | $2.1M | $38.6M | $31.6M | $33.4M | $49.6M | $14.5M | $11.9M | $22.6M | $18.3M | $32.1M | |
| Total Current Liabilities | $1.3M | $1.7M | $5.4M | $4.7M | $5.5M | $20.7M | $11.2M | $14.2M | $10.8M | $8.4M | $28.6M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $880.0K | $979.0K | $1.1M | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $1.3M | $1.7M | $10.7M | $10.7M | $9.0M | $30.8M | $12.7M | $14.6M | $10.8M | $8.4M | $28.6M | |
| Stockholders' Equity | $5.2M | $394.0K | $23.8M | $18.1M | $24.4M | $18.8M | $1.9M | -$2.8M | $11.8M | $9.8M | $3.5M | |
| Retained Earnings | $0.00 | -$7.1M | -$9.4M | -$32.4M | -$39.8M | -$66.5M | -$82.5M | -$94.5M | -$119.0M | -$130.2M | -$136.4M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$4.0M | -$1.3M | -$4.2M | -$10.1M | -$7.3M | -$15.1M | -$16.8M | -$12.7M | -$17.4M | -$14.8M | -$13.7M | |
| Capital Expenditure | -$77.8K | $0.00 | -$5.7K | -$8.0K | -$3.0K | $0.00 | -$18.0K | $0.00 | -$298.0K | -$8.0K | -$64.0K | |
| Free Cash Flow | -$4.1M | -$1.3M | -$4.2M | -$10.1M | -$7.3M | -$15.1M | -$16.8M | -$12.7M | -$17.6M | -$14.8M | -$13.8M | |
| Investing Cash Flow | -$178.7K | -$128.0K | $1.5M | $229.0K | -$3.0K | $1.0M | $791.0K | $0.00 | -$298.0K | -$8.0K | -$64.0K | |
| Financing Cash Flow | $4.3M | $1.2M | $2.4M | $11.2M | $6.0M | $33.8M | -$1.3M | $11.0M | $36.8M | $10.6M | $21.8M | |
| Issuance of Stock | $0.00 | $0.00 | $0.00 | $13.6M | $3.7M | $32.1M | $0.00 | $16.9M | $40.3M | $13.8M | $2.7M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$1.5M | $0.00 | -$3.5M | -$3.2M | -$887.0K | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | $3.5M | $2.6M | $969.0K | $1.0M | -$2.6M | $0.00 | $0.00 | $20.0M | |
| Stock Based Comp. | $0.00 | $2.3M | $214.1K | $333.0K | $616.0K | $6.4M | $1.8M | -$71.0K | $71.0K | $482.0K | $339.0K | |
| Net Change in Cash | $2.1M | -$1.5M | -$298.6K | $1.3M | -$1.2M | $19.3M | -$17.5M | -$1.9M | $19.4M | -$4.8M | $9.2M |
Dilution Tracker
Shares outstanding grew 369957792.6% over 5 years — significant dilution
Shares Outstanding
16M
5-Year Share Growth
+369957792.6%
Stock Issuance (TTM)
$2.7M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.01 | 0.01 | 3.32 | 1.61 | 14.38 | 15.91 | |
| Change vs Prior % | — | — | — | — | -100.0% | 194669.6% | 49.8% | 29147.9% | -51.6% | 794.8% | 10.7% | |
| Stock Issuance | $0.00 | $0.00 | $0.00 | $13.6M | $3.7M | $32.1M | $0.00 | $16.9M | $40.3M | $13.8M | $2.7M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$1.5M | $0.00 | -$3.5M | -$3.2M | -$887.0K | |
| Stock Based Comp. | $0.00 | $2.3M | $214.1K | $333.0K | $616.0K | $6.4M | $1.8M | -$71.0K | $71.0K | $482.0K | $339.0K |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 100.0% | -52.2% | -247.9% | 100.0% | — | — | — | — | — | 100.0% | 107.5% | |
| Operating Margin % | -3132.1% | -263.4% | -341.2% | -14675.8% | — | — | — | — | — | -3939.1% | -3129.0% | |
| Net Margin % | -2570.4% | -335.7% | -157.0% | -11927.5% | — | — | — | — | — | -3509.7% | -3575.1% | |
| EBITDA Margin % | -2937.9% | -262.8% | -335.4% | -13011.7% | — | — | — | — | — | -3451.9% | -3203.2% | |
| FCF Margin % | -2830.7% | -92.2% | -290.6% | -8434.2% | — | — | — | — | — | -4633.8% | -3994.8% | |
| ROE % | -70.8% | -1242.9% | -9.6% | -79.1% | -27.0% | -141.9% | -849.6% | 432.6% | -207.6% | -114.3% | -152.8% | |
| ROA % | -56.3% | -234.0% | -5.9% | -45.3% | -19.8% | -53.7% | -110.4% | -100.3% | -108.2% | -61.5% | -38.4% | |
| ROIC % | -71.4% | -956.8% | -9.5% | -48.6% | -28.3% | -91.5% | -527.0% | 1704.4% | -203.8% | -112.3% | -41.8% | |
| R&D / Revenue % | 0.0% | 0.0% | 0.0% | 5305.8% | — | — | — | — | — | 2062.8% | 1599.7% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -60.5% | 918.3% | 0.1% | -91.8% | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | -60.5% | -631.5% | -375.3% | 103.3% | -100.0% | 0.0% | -13.2% | 100.0% | 0.0% | 0.0% | |
| Operating Income | -221.3% | 14.4% | -29.6% | -253.5% | 52.8% | -219.2% | -29.8% | 50.3% | -59.0% | 53.7% | |
| Net Income | -221.1% | -33.0% | 53.2% | -524.4% | 53.9% | -303.6% | 39.7% | 25.9% | -106.0% | 54.2% | |
| EPS (Diluted) | 0.0% | 0.0% | 0.0% | 0.0% | -795.8% | 95.3% | 59.8% | 81.0% | 99.7% | 95.1% | |
| Operating Cash Flow | -96.0% | 66.2% | -215.2% | -138.6% | 28.3% | -107.6% | -11.7% | 24.2% | -36.1% | 14.6% | |
| Free Cash Flow | -99.8% | 66.8% | -215.6% | -138.5% | 28.3% | -107.5% | -11.9% | 24.3% | -38.5% | 16.0% | |
| R&D Expense | 0.0% | 0.0% | 0.0% | 0.0% | -33.8% | 236.6% | -51.2% | 2.5% | -14.2% | 8.3% | |
| SG&A Expense | 205.5% | 1028.2% | -58.4% | 202.7% | 6.0% | 201.4% | -19.4% | 0.6% | 14.1% | -44.7% | |
| Total Assets | 19.9% | -68.0% | 1744.1% | -18.1% | 5.7% | 48.6% | -70.7% | -18.4% | 90.9% | -19.4% | |
| Book Value / Share | 0.0% | 0.0% | 0.0% | 0.0% | 2270605.6% | -100.0% | -93.3% | -100.5% | 986.2% | -90.7% | |
| Debt | 0.0% | 0.0% | 0.0% | -66.8% | 176.9% | -59.3% | 243.9% | -65.2% | 3.8% | 3.7% | |
| Diluted Shares | 0.0% | 0.0% | 0.0% | 0.0% | -100.0% | 194669.6% | 49.8% | 29147.9% | -51.6% | 794.8% |
Valuation
P/E (TTM)At Loss
P/S44.50
P/B4.34
10Y Low / Med / High0.16 / 1480.88 / 36809.74
EV/EBITDAAt Loss
10Y Low / Med / High0.14 / 0.49 / 0.67
EV/Revenue59.87
10Y Low / Med / High1.82 / 7.01 / 5548142.83
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$1.18
Tangible Book / Share
$0.22
Net Current Assets / Share
$0.20
Cash / Share
$1.07
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | 0.00 | 0.00 | 0.00 | -46.52 | -5.19 | -110.21 | -7.76 | -0.05 | -0.07 | -1.38 | -1.24 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 5548147.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 48.53 | 44.50 | |
| P/B Ratio | 0.00 | 0.00 | 0.00 | 36809.74 | 1.40 | 3512.00 | 1480.88 | -398.69 | 0.16 | 1.58 | 4.34 | |
| EV/EBITDA | 0.49 | 0.14 | -0.54 | -42639.76 | -6.05 | -2559.31 | -161.92 | -97.31 | 0.67 | -0.20 | -1.87 | |
| EV/Revenue | -14.46 | -0.37 | 1.82 | 5548142.83 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.01 | 59.87 |
Analyst Estimates & Quality
Altman Z-Score
-6.63
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 |
|---|---|---|
| Revenue | $25.0K | $85.9M |
| Net Income | -$11.5M | -$12.4M |
| EPS | $-0.80 | $-0.86 |
| # Analysts (EPS) | 1 | 1 |
Revenue Segments
By Product
| Segment | 2025 |
|---|---|
| License | $320.0K |